Inhibition of the p53/hDM2 protein-protein interaction by cyclometallated iridium(III) compounds

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Organometallic Chemistry

Background:

• Inactivation of the p53 transcription factor is common in tumorigenesis.
• Human double minute 2 (hDM2) is a key negative regulator of p53, promoting its degradation.
• Disrupting the p53/hDM2 interaction is a potential anti-cancer strategy.

Purpose of the Study:

• To synthesize and evaluate organometallic iridium(III) compounds as inhibitors of the p53/hDM2 protein-protein interaction.
• To identify novel compounds that can disrupt this critical interaction in cancer cells.

Main Methods:

• Synthesis of a library of organometallic iridium(III) compounds.
• Evaluation of compound efficacy in disrupting the p53/hDM2 interaction.
• Assessment of anti-proliferative and apoptosis-inducing activities in cancer cell lines.

Main Results:

• A novel cyclometallated iridium(III) compound, designated 1 [Ir(eppy)2(dcphen)](PF6), was identified.
• Compound 1 effectively blocked the p53/hDM2 interaction in human amelanotic melanoma cells.
• Compound 1 demonstrated anti-proliferative effects and induced apoptosis in tested cancer cell lines.

Conclusions:

• Compound 1 is the first reported organometallic inhibitor of the p53/hDM2 protein-protein interaction.
• This compound shows promise as a therapeutic agent by targeting a crucial cancer pathway.
• Further investigation into iridium(III) compounds for cancer therapy is warranted.